Operating Segments

3 Months Ended

Mar. 31, 2024

Operating Segments

Operating Segments

Note 7. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended
	March 31,
	2024		2023
Revenues
Specialized BioTherapeutics	$	117,029	$	155,365
Public Health Solutions		—		101,813
Total	$	117,029	$	257,178
Income (loss) from Operations
Specialized BioTherapeutics	$	(860,604)	$	(910,377)
Public Health Solutions		(45,997)		427
Corporate		(1,210,490)		(1,240,739)
Total	$	(2,117,091)	$	(2,150,689)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	953	$	1,071
Public Health Solutions		159		178
Corporate		476		536
Total	$	1,588	$	1,785
Other (Expense) Income, Net
Specialized BioTherapeutics	$	7,540	$	6,082
Corporate		194,224		(62,699)
Total	$	201,764	$	(56,617)
Share-Based Compensation
Specialized BioTherapeutics	$	20,672	$	27,427
Public Health Solutions		588		994
Corporate		38,701		45,213
Total	$	59,961	$	73,634

	As of		As of
	March 31,		December 31,
	2024		2023
Identifiable Assets
Specialized BioTherapeutics	$	301,709	$	272,099
Public Health Solutions		120,475		3,976
Corporate		7,636,201		9,521,251
Total	$	8,058,385	$	9,797,326